QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 0.0561
-- x --
-- x --
-- - --
$ 0.05 - $ 0.19
71,707
na
na
nm
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

 hc-wainwright--co-downgrades-unity-biotechnology-to-neutral-lowers-price-target-to-2

HC Wainwright & Co. analyst Matthew Caufield downgrades Unity Biotechnology (NASDAQ:UBX) from Buy to Neutral and lowers ...

 unity-biotechnology-announces-complete-36-week-results-from-phase-2b-aspire-clinical-trial-of-intravitreal-ubx1325-in-patients-with-diabetic-macular-edema

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-...

 chardan-capital-maintains-buy-on-unity-biotechnology-maintains-4-price-target

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $4 price target.

 unity-biotechnology-announces-publication-in-nejm-article-titled-safety-and-efficacy-of-senolytic-ubx1325-in-diabetic-macular-edema-evidence-highlighting-the-potential-of-senolytic-therapeutics-to-provide-long-term-improvements-in-vision-in-diabetic-macular-edema

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reve...

 hc-wainwright--co-reiterates-buy-on-unity-biotechnology-maintains-4-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:UBX) with a Buy and maintains $4 pri...

 chardan-capital-maintains-buy-on-unity-biotechnology-lowers-price-target-to-4

Chardan Capital analyst Daniil Gataulin maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and lowers the price target fr...

 hc-wainwright--co-maintains-buy-on-unity-biotechnology-lowers-price-target-to-4

HC Wainwright & Co. analyst Matthew Caufield maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and lowers the price ...

 hc-wainwright--co-maintains-buy-on-unity-biotechnology-lowers-price-target-to-4

HC Wainwright & Co. analyst Matthew Caufield maintains Unity Biotechnology (NASDAQ:UBX) with a Buy and lowers the price ...

 unity-biotechnology-unveils-mixed-data-from-study-for-diabetes-related-blindness-stock-falls

Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION